<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430157</url>
  </required_header>
  <id_info>
    <org_study_id>IPR107498</org_study_id>
    <nct_id>NCT00430157</nct_id>
  </id_info>
  <brief_title>Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber</brief_title>
  <official_title>An 8 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is in patients with seasonal allergic rhinitis (SAR) and will compare the effect&#xD;
      versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.&#xD;
      GSK256066 is a potent and highly selective phosphodiesterase-4 (PDE4) inhibitor, currently in&#xD;
      development by GSK for the treatment of allergic rhinitis, asthma and COPD.&#xD;
&#xD;
      Subjects will be selected on the basis that they display a defined moderate response to the&#xD;
      pre-determined dose used.&#xD;
&#xD;
      This study aims to explore the actions of repeat doses of intranasal GSK256066 in patients&#xD;
      with Seasonal Allergic Rhinitis in the Vienna Challenge Chamber compared to placebo.&#xD;
&#xD;
      12-lead ECG, vital signs and adverse event enquiries will be made throughout the study. Nasal&#xD;
      examination, symptom scores (TNSS), nasal lavage, nasal scrape and allergen challenge&#xD;
      assessments will also be performed at various time points throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction)</measure>
    <time_frame>1-4h post-dose period spent in the Vienna Challenge Chamber on Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction)</measure>
    <time_frame>1-4h post morning dose period spent in the Vienna Challenge Chamber on Day 2.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <condition>Seasonal Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK256066</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is healthy.&#xD;
&#xD;
          -  They are aged 18 to 50 years inclusive.&#xD;
&#xD;
          -  Body mass index less than 29.0 kg/mÂ² with weight range of 55.0kg (females 50kg) to&#xD;
             95.0kg inclusive.&#xD;
&#xD;
          -  They have a history of seasonal allergic rhinitis&#xD;
&#xD;
          -  They exhibit a moderate response to 1500 grass pollen grains/m3 after 2h in the Vienna&#xD;
             Challenge Chamber,&#xD;
&#xD;
          -  They have a positive skin prick test for grass pollen at or within the 12 months&#xD;
             preceding the screening visit.&#xD;
&#xD;
          -  They have a positive RAST for grass pollen at or within the 12 months preceding the&#xD;
             screening visit.&#xD;
&#xD;
          -  They are current non-smokers who have not used any tobacco products in the 6 months&#xD;
             preceding the screening visit&#xD;
&#xD;
          -  They must have a baseline FEV1&gt;80% predicted and a baseline FEV1 (maximum recorded&#xD;
             value)/ FVC (associated value)&gt;70% predicted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  Women of childbearing potential who are unwilling or unable to use an appropriate&#xD;
             method of contraception.&#xD;
&#xD;
          -  any structural nasal abnormalities or nasal polyposis, a history of frequent&#xD;
             nosebleeds, recent nasal surgery or recent (within 2 weeks) or ongoing upper&#xD;
             respiratory tract infection.&#xD;
&#xD;
          -  The subject is likely to be unable to abstain from salbutamol use for 8 hours before a&#xD;
             challenge&#xD;
&#xD;
          -  The subject has a history of drug or other allergy&#xD;
&#xD;
          -  The subject is concurrently participating in another clinical study in the past 3&#xD;
             months&#xD;
&#xD;
          -  A supine blood pressure that is persistently higher than 140/90 millimetres of mercury&#xD;
             (mmHg) at screening&#xD;
&#xD;
          -  A supine mean heart rate outside the range 40-90 beats per minute (bpm) at screening.&#xD;
&#xD;
          -  The subject has donated a unit of blood within the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1150</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vienna Challenge Chamber</keyword>
  <keyword>Seasonal Allergic Rhinitis</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

